Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Qingxiang Guo

Showing results (81-90 of 85) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 85 results.
Journal of Medicinal Chemistry|March 9, 2018
Discovery of N1-(4-((7-Cyclopentyl-6-(dimethylcarbamoyl)-7 H-pyrrolo[2,3- d]pyrimidin-2-yl)amino)phenyl)- N8-hydroxyoctanediamide as a Novel Inhibitor Targeting Cyclin-dependent Kinase 4/9 (CDK4/9) and Histone Deacetlyase1 (HDAC1) against Malignant CancerYongtao Li, Xiaohe Luo, Qingxiang Guo, et al.
Theranostics|November 16, 2018
Novel hybrid molecule overcomes the limited response of solid tumours to HDAC inhibitors via suppressing JAK1-STAT3-BCL2 signallingZhi Huang, Wei Zhou, Yongtao Li, et al.
Journal of Medicinal Chemistry|January 9, 2018
Highly Selective, Potent, and Oral mTOR Inhibitor for Treatment of Cancer as Autophagy InducerQingxiang Guo, Chenhua Yu, Chao Zhang, et al.
Science Advances|April 9, 2025
Androgen receptor-regulated lncRNA PRCAT71 promotes AR signaling through the interaction with KHSRP in prostate cancerYongyong Yang, Ting-You Wang, Qianru Li, et al.
Nature Communications|March 20, 2026
Tumor-specific lncRNA IGF1R-AS1 trans-regulates chromatin interactions associated with oncogenic MYC signalingYongyong Yang, Ting-You Wang, Joshua Fry, et al.
Pageof 9

Showing results (81-90 of 85) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 85 results.
Journal of Medicinal Chemistry|March 9, 2018
Discovery of N1-(4-((7-Cyclopentyl-6-(dimethylcarbamoyl)-7 H-pyrrolo[2,3- d]pyrimidin-2-yl)amino)phenyl)- N8-hydroxyoctanediamide as a Novel Inhibitor Targeting Cyclin-dependent Kinase 4/9 (CDK4/9) and Histone Deacetlyase1 (HDAC1) against Malignant CancerYongtao Li, Xiaohe Luo, Qingxiang Guo, et al.
Theranostics|November 16, 2018
Novel hybrid molecule overcomes the limited response of solid tumours to HDAC inhibitors via suppressing JAK1-STAT3-BCL2 signallingZhi Huang, Wei Zhou, Yongtao Li, et al.
Journal of Medicinal Chemistry|January 9, 2018
Highly Selective, Potent, and Oral mTOR Inhibitor for Treatment of Cancer as Autophagy InducerQingxiang Guo, Chenhua Yu, Chao Zhang, et al.
Science Advances|April 9, 2025
Androgen receptor-regulated lncRNA PRCAT71 promotes AR signaling through the interaction with KHSRP in prostate cancerYongyong Yang, Ting-You Wang, Qianru Li, et al.
Nature Communications|March 20, 2026
Tumor-specific lncRNA IGF1R-AS1 trans-regulates chromatin interactions associated with oncogenic MYC signalingYongyong Yang, Ting-You Wang, Joshua Fry, et al.
Pageof 9